Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 20;15(10):2502. doi: 10.3390/pharmaceutics15102502

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

(a). Simulated AVA concentration vs. time plots from 50 virtual individuals (i.e., from one virtual trial replicate) who took vinpocetine tablets (5 mg/10 mg/15 mg) three times a day (every 8 h). The red line marks the concentration range between the lower 5% of Cmin values and the higher 95% of the Cmax values, which are considered to be safe and efficacious based on the clinical therapeutic regimen of 5 mg three times a day. (Concentration of AVA in μg/L, time in h). (b). Simulated AVA concentration vs. time plots from 50 virtual individuals (i.e., from one virtual trial replicate) who took vinpocetine tablets (15 mg/30 mg/60 mg) once a day (every 24 h). The red line marks the concentration range between the lower 5% of Cmin values and the higher 95% of the Cmax values, which are considered to be safe and efficacious based on the clinical therapeutic regimen of 5 mg three times a day. (Concentration of AVA in μg/L, time in h). (c). Summary statistics of the AVA Cmax values based on the simulated dosage regimens of vinpocetine from ten trial replicates. The concentration of AVA on the y-axis is expressed in micrograms per liter (μg/L). (d). Summary statistics of the AVA Cmin values based on the simulated dosage regimens of vinpocetine from ten trial replicates. The concentration of AVA on the y-axis is expressed in micrograms per liter (μg/L).

(a). Simulated AVA concentration vs. time plots from 50 virtual individuals (i.e., from one virtual trial replicate) who took vinpocetine tablets (5 mg/10 mg/15 mg) three times a day (every 8 h). The red line marks the concentration range between the lower 5% of Cmin values and the higher 95% of the Cmax values, which are considered to be safe and efficacious based on the clinical therapeutic regimen of 5 mg three times a day. (Concentration of AVA in μg/L, time in h). (b). Simulated AVA concentration vs. time plots from 50 virtual individuals (i.e., from one virtual trial replicate) who took vinpocetine tablets (15 mg/30 mg/60 mg) once a day (every 24 h). The red line marks the concentration range between the lower 5% of Cmin values and the higher 95% of the Cmax values, which are considered to be safe and efficacious based on the clinical therapeutic regimen of 5 mg three times a day. (Concentration of AVA in μg/L, time in h). (c). Summary statistics of the AVA Cmax values based on the simulated dosage regimens of vinpocetine from ten trial replicates. The concentration of AVA on the y-axis is expressed in micrograms per liter (μg/L). (d). Summary statistics of the AVA Cmin values based on the simulated dosage regimens of vinpocetine from ten trial replicates. The concentration of AVA on the y-axis is expressed in micrograms per liter (μg/L).